Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol
about
Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment coursePulmonary arterial hypertension: a comparison between children and adultsRecent strategies in treatment of pulmonary arterial hypertension, a reviewPulmonary arterial hypertension: an updateAttenuation of monocrotaline-induced pulmonary hypertension by luminal adeno-associated virus serotype 9 gene transfer of prostacyclin synthaseThe emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension.Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updatesLong-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settingsShort- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension.Overview of current therapeutic approaches for pulmonary hypertension.Pulmonary arterial hypertension: advances in pathophysiology and management.Epoprostenol treatment in children with severe pulmonary hypertension.Update in pulmonary hypertension 2005.Current understanding of the role of bosentan in inoperable chronic thromboembolic pulmonary hypertension.Treatment of pulmonary hypertensionReview of bosentan in the management of pulmonary arterial hypertensionCost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study.Expert opinion on available options treating pulmonary arterial hypertension.Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost.Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient.Therapeutic advances in pulmonary arterial hypertension.Safety and tolerability of bosentan in the management of pulmonary arterial hypertension.Beneficial and adverse effects of bosentan treatment in korean patients with pulmonary artery hypertension.Advances in therapies for pediatric pulmonary arterial hypertension.Bosentan for the treatment of adult pulmonary hypertension.Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension.Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension.Treatment of pulmonary arterial hypertension with targeted therapies.Practical considerations for the pharmacotherapy of pulmonary arterial hypertension.Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists.Bosentan for pulmonary hypertension and other pulmonary diseases: emerging evidence.Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension.The effect of bosentan in patients with a failing Fontan circulation.Out with the old, in with the new: an updated risk stratification equation for pulmonary arterial hypertension.Exercise training in pulmonary arterial hypertension.First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.Bosentan for the treatment of scleroderma
P2860
Q27023074-8A1F22BF-6C25-49A4-AADF-E95448B1E6DEQ27687320-E620B9D1-216A-4A00-83CB-9FD4D53F757BQ28084702-FDD455A9-6909-41B5-9647-01E7271EACCAQ30472109-2EAD4DCF-73BD-4227-B4ED-2FF2E158EA9FQ33782838-D41F23AD-955D-4DC2-907B-6E902EB1A664Q33844740-0242386A-8A1C-482C-87E2-DD0836F71E0AQ33965904-612D028E-E363-4955-A127-F5D1CDC144B7Q34254924-C6DBFFE0-886C-413D-89BA-C487CDBE2251Q35076114-4367F25B-E478-4406-9668-08E94FCAD83AQ35412362-46D0AEB6-9D96-406B-AAD4-AF3011AFC327Q35732584-ACBC0545-FF99-4584-AD21-BF1D81CE7FF9Q35954745-5C5CE54C-8CDC-4B4F-BDB5-CD0378749CCCQ36403168-A32A0599-305E-43C0-8F61-C1D87674B0F8Q36491793-8F3EBF7F-ABF1-423D-8817-03E0F4C34FD9Q36577681-BE54001E-EAA2-4CC4-8E54-5E4FFFBA67D1Q36596818-D0D69E91-B118-43EF-ABB2-1D5550423793Q36789240-D50359D6-4054-4D33-8D26-19622F37C16EQ36967262-63D1EA82-7E68-4AF9-987B-84B99CEC1B71Q37019838-10DB15A1-498F-439D-BD73-40FD7E46673CQ37133820-FA19B089-A2C1-472E-A89F-ADEB790CE0C1Q37302470-750BE058-506D-4EF9-9266-70BC107102BCQ37362631-2FAFB1E2-1510-4AC6-92F8-B1F5904CC866Q37403190-BA041F38-5BF1-419C-90FA-7E59AF0FE9FAQ37408703-BEB638A8-0FC6-42F2-8BFF-3BDEF0DD12B8Q37755020-523DCBF3-9D77-44B9-86A5-D1DD9B3D10B9Q37822722-9EEE88D1-4F10-4CB3-BDBE-F45D11E2F25EQ37866804-7F7118C1-14A8-4F3B-9E44-283192A93A8FQ37889264-6DDC16A7-BAD6-4BED-9094-0CF5F3AEB2B6Q37902509-A77FCE9C-BDEF-42FE-9052-1C5A75CABF5EQ38027095-57B5F45E-7696-4387-B34A-6BD2F6EC93F3Q38542993-BD8956ED-0BEA-4D03-8D7A-9BCF14D8B6D0Q39941690-21C614BC-5564-4D1C-B46F-FC5CF8E81334Q42595705-AAC83A8F-AF60-438E-A12A-8206B221BC56Q43218254-E4DDB3AF-4D22-492A-8A87-33A1658E3079Q45865709-C624E658-BE48-4F57-BB55-C4925773A06AQ45972746-A9A42539-C8FF-4239-9031-1310B0EEE0A3Q51691932-15DDA510-D60A-4E0A-9DF2-0C7D10CE2044Q51732363-F6319D69-389D-4CEF-B318-28562C605996Q52931065-598C57C7-AF8D-4AF1-96E5-0469D6EFA46AQ56978245-C920CE77-4072-4355-968E-A4385214733A
P2860
Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Survival in patients with clas ...... ed on intravenous epoprostenol
@ast
Survival in patients with clas ...... ed on intravenous epoprostenol
@en
type
label
Survival in patients with clas ...... ed on intravenous epoprostenol
@ast
Survival in patients with clas ...... ed on intravenous epoprostenol
@en
prefLabel
Survival in patients with clas ...... ed on intravenous epoprostenol
@ast
Survival in patients with clas ...... ed on intravenous epoprostenol
@en
P2093
P2860
P50
P356
P1433
P1476
Survival in patients with clas ...... ed on intravenous epoprostenol
@en
P2093
D B Badesch
G Simonneau
M Rainisio
V V McLaughlin
P2860
P304
P356
10.1136/THX.2005.040618
P407
P577
2005-07-29T00:00:00Z